



# Marksans Pharma Ltd.

September 23, 2025

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001  
**Scrip Code: 524404**

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block - G  
Bandra-Kurla Complex  
Bandra (East), Mumbai - 400051  
**Symbol: MARKSANS**

**Sub: Press Release**

**Marksans Pharma Limited's wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.**

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for the below-mentioned products from UK MHRA:

1. Moxonidine 200 microgram Tablets
2. Moxonidine 400 microgram Tablets

Please take the above information on record.

Thanking you.

Yours faithfully

For **Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary**

**About Marksans Pharma Ltd**

Marksans Pharma Limited ([www.marksanspharma.com](http://www.marksanspharma.com)) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

**Marksans Pharma Ltd.**

11<sup>th</sup> Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: [companysecretary@marksanspharma.com](mailto:companysecretary@marksanspharma.com)

[www.marksanspharma.com](http://www.marksanspharma.com)